|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.825 USD | +11.08% |
|
+47.35% | -41.07% |
| Apr. 26 | Foreign automakers eager for Chinese partners at Beijing auto show | RE |
| Apr. 25 | Battle for 'tech luxury' in China as EVs get smarter - and cheaper | RE |
Seres Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 126.33 million compared to USD 7.13 million a year ago. Net loss was USD 113.72 million compared to USD 250.16 million a year ago.
Basic loss per share from continuing operations was USD 0.89 compared to USD 2.31 a year ago. Diluted loss per share from continuing operations was USD 0.89 compared to USD 2.31 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -41.07% | 125M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
SERES THERAPEUTICS, INC. 
